Clinical Trial Update: Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia. [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing bifeprunox to olanzapine in weight outcomes among outpatients with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)
• olanzapine (olanzapine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED